ClinicalTrials.gg
Not yet recruitingNCT07682337Updated Jul 2, 2026

Study of Single and Multiple Oral Doses of SCB0020160 in Healthy Adult Male Subjects

A Phase 1 interventional study of SCB0020160 and Placebo in Solid Tumor, Obesity and Idiopathic Pulmonary Fibrosis, sponsored by SCBIO Inc.. Not yet recruiting at 1 site in Australia. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by SCBIO Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 188 studies in Obesity with a site in Australia — 56 open to participants now, 74 under way, 34 of them phase 3. Obesity · Australia.

Planned enrollment
112th of 169
74 · median 180
Started
2026
with 40 others
Phase 1
33 of 188
15 open now
Primary completion
2027-06
later than 23 of 73 live
Registered
173rd of 188
by date

Among the 188 studies in Obesity with a site in Australia, this one is the 112th largest by planned enrollment of the 169 interventional ones that give a count, is one of 41 that started in 2026, is one of 33 in phase 1, reaches primary completion later than 23 of the 73 other live ones, and was the 173rd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

56 of the 188 studies in Obesity with a site in Australia are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 65 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 188 studies in Obesity with a site in Australia, or all of them as a file.
02

Study summary

This study aims to evaluate the safety, tolerability, pharmacokinetics, and food effect of a new investigational medicine called SCB0020160 in healthy adult men. This is the first time SCB0020160 will be administered to humans.

Healthy adult men aged 18 to 65 years who meet the study eligibility criteria.

Study details

Participants will be randomly assigned to receive either SCB0020160 or placebo. The study includes single-dose and multiple-dose treatment periods, as well as an assessment of the effect of food on the absorption of SCB0020160.

Participants will undergo safety assessments including physical examinations, vital signs, ECGs, blood and urine tests, and monitoring of adverse events. The study will also assess how SCB0020160 is processed by the body.

There is no direct health benefit expected from participation. The results may help determine safe dose levels and support future clinical development of SCB0020160.

Read the detailed description

This study evaluates the safety, tolerability, and pharmacokinetics of SCB0020160 or placebo following single and multiple oral doses in healthy adult male subjects. A total of 74 subjects were planned, including 64 target subjects (8 per dose group) and 10 substitute subjects. The study may be completed without enrolling substitute subjects if all 64 target subjects complete the study.

03

Conditions studied

  • Solid Tumor
  • Obesity
  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult male volunteers in the opinion of the principal investigator or delegate, aged 18 to 65 years at screening
  • Body weight more Than or equals to 45.0 kilograms per square meter at screening, with a (BMI) of more than or equals to18.0-kilogram Meter square and less than or equals to 32.0 Kilograms per meter square

    • Body Mass Index (BMI, kilograms per square meter.) = Weight (kilogram)/[Height square meter]
  • Eligible to participate in the study based on the results of physical examination, clinical laboratory tests, history taking, and other examinations performed at screening, as determined by the principal investigator or delegate
  • Has voluntarily decided to participate and provided written or electronic consent to comply with the precautions after receiving a full explanation of the study and fully understanding it

Exclusion criteria

Exclusion Criteria:

  • Has a history of or currently has any disease, including hepatobiliary (severe liver impairment, viral hepatitis, etc.), renal (severe renal impairment, etc.), neurological, immunological, respiratory, digestive, endocrine, hematologic and oncologic, cardiovascular (Torsades de pointes, etc.), urological, psychiatric (mood disorders, obsessive compulsive disorder, etc.), and sexual function disorders
  • Has a history of or currently has a gastrointestinal disease (Crohn's disease, ulcerative colitis, etc.) that may affect the safety and pharmacokinetic evaluation of the product, or has a history of gastrointestinal surgery (except for simple appendectomy or hernia surgery)
  • Has a history of to the active pharmaceutical ingredient and components of the investigational product, drugs in the same class as the active pharmaceutical ingredient, or other drugs (aspirin, antibiotics, etc.)
  • Has genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose galactose malabsorption
  • Has any of the following results in vital signs measured in a sitting position after resting for at least 5 minutes at screening
  • Systolic blood pressure more than 80 millimeters of mercury or greater than or equal to140 mmHg
  • Diastolic blood pressure less than 45 millimeters of mercury or greater than or equal to140 mmHg 90 millimeters of mercury
  • Pulse rate less than 45 beats/min or > 105 beats/min
  • Has any of the following results in the 12-lead measured in a semi-supine position after resting for at least 5 minutes at screening, or has clinically significant rhythm findings
  • less than 450 msec
  • Has any of the following results in the screening clinical laboratory tests
  • Estimated (eGFR) (CKD-EPI equation) \< 90 mL/min/1.73 m²
  • Fasting serum glucose more than 5.4 millimoles per liter. or less than 3.0 millimoles per liter.
  • or ALT 1.5 X the (ULN)
  • Total cholesterol less than 5.5 millimoles per liter
  • Triglyceride less than 2.0 millimoles per liter.
  • Drinks alcohol persistently (less than 21 units/week, 1 unit = 10 gram = 12.5 milli liter of pure alcohol) or is unable to refrain from alcohol consumption from 3 days prior to the expected first dose of the investigational product until the end of the study
  • Tested positive for the breath alcohol test at screening or at check-in on D-1 10) Smokers (However, those who quit smoking 3 months prior to the expected first dose of the investigational product may be eligible as subjects)
  • Tested positive for the urine cotinine test at screening or at check-in on D-1, even if they do not smoke
  • Has taken any prescribed drugs or herbal medicines within 2 weeks prior to the expected first dose, or has taken any over-the-counter (OTC) drugs, health functional foods including liver supplements, or vitamins within 1 week (However, they may participate in the study if the investigator deems their other conditions appropriate), or is expected to take any of the said agents
  • Has taken drugs that induce drug-metabolizing enzymes, such as barbiturates, or drugs that inhibit drug metabolism, such as clarithromycin, within 1 month prior to the expected first dose
  • Has a history of alcohol or drug abuse, or has shown a positive result for abused drugs in a urine drug test at screening or at check-in on D-1
  • Has participated in another study (including bioequivalence studies) and received an investigational product within 3 months prior to the first dose
  • Has donated whole blood within 2 months, donated blood components within 1 month, or received a blood transfusion within 1 month prior to the expected first dose
  • Has persistently consumed excessive amounts of caffeine (> 5 units/day, 1 unit = 80 mg of caffeine), or is unable to refrain from consuming caffeine-containing foods (coffee, tea (black tea, green tea, etc.), carbonated beverages, coffee-flavored milk, health tonics, energy drinks, etc.) from 3 days prior to the expected first dose of the investigational product until the end of the study
  • Has consumed grapefruit, grapefruit juice, or grapefruit-containing foods from 3 days prior to the expected first dose of the investigational product until the end of the study, or is unable to refrain from consuming grapefruit-containing foods during this period
  • Has unusual eating habits (e.g., consuming more than 1L of grapefruit juice per day) or is unable to consume the standard diet provided by the study site during the inpatient period
  • Tested positive for serological tests ( test, test, (HIV) test, syphilis test)
  • Subjects who, or whose spouse (or partner) is a woman of , are unable or unwilling to use methods of considered highly effective for the entire period of the study and for at least 90 days after the last dose of the investigational product, and who do not agree to avoid donating sperm/eggs during this period.

[Methods of contraception considered highly effective]

  • Intrauterine devices and intrauterine hormone-releasing systems with a proven contraception failure rate (\< 1%/year) plus the use of a male condom
  • Bilateral tubal occlusion or bilateral tubal ligation plus the use of a male condom
  • Azoospermia is confirmed by sperm test after vasectomy
  • Hormonal contraception (e.g., combined oral contraceptive, progestogen-only oral contraceptive), contraceptive patch, vaginal ring, injection, subdermal contraceptive implant); however, hormonal contraception is limited to cases where it is being used for 28 days or longer prior to the administration of the investigational product and can be continuously used during the study period and up to 90 days after the last dose plus the use of a male condom.
  • Sexual abstinence, if it is the usual and preferred method of contraception.
  • Those judged by the principal investigator or delegate to be ineligible for participation in the study for reasons other than the above-mentioned criteria (non-compliance with instructions, etc.)
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
74 participants (estimated)

Study arms

  • Experimental
    SCB0020160

    Single and multiple oral doses of SCB0020160

    Drug: SCB0020160

  • Placebo comparator
    Placebo

    Matching placebo administered under the same dosing conditions

    Drug: Placebo

Interventions

  • DrugSCB0020160

    Single and multiple oral doses of SCB0020160 administered under fasting conditions. A food-effect evaluation following a single oral dose will be conducted in Part A Cohort 4.

  • DrugPlacebo

    Matching placebo administered orally under the same dosing conditions as SCB0020160, including participation in the food-effect evaluation in Part A Cohort 4

06

What researchers measure

Primary outcomes

  1. Incidence and frequency of adverse events, adverse drug reactions, serious adverse events, and serious adverse drug reactions

    Adverse event analysis will be conducted on Treatment Emergent Adverse Events (TEAEs)

    Time frame: From first dose through Post-Study Visit (up to Day 33)

  2. For Physical examination to evaluate General Appearance

    For General Appearance assessments are: Level of consciousness (alert, oriented) Nutritional status (well/poorly nourished) Build and posture Signs of distress (pain, dyspnea, fatigue) Hygiene and grooming

    Time frame: From first dose through Post-Study Visit (up to Day 33)

  3. For Physical examination to evaluate HEENT

    For HEENT assessments are: Head: shape, scalp lesions Eyes: pupil size/reactivity (PERRLA), vision, conjunctiva (pallor/icterus) Ears: hearing, discharge Nose: obstruction, discharge Throat: oral mucosa, tonsils, pharynx

    Time frame: From first dose through Post-Study Visit (up to Day 33)

  4. For Physical examination to evaluate Neck (incl Thyroid & Nodes)

    for Neck (incl Thyroid \& Nodes) assessment are: Thyroid size, nodules, tenderness Cervical lymphadenopathy Neck mobility Jugular venous pressure (if relevant

    Time frame: From first dose through Post-Study Visit (up to Day 33)

  5. For Physical examination to evaluate Cardiovascular

    For Cardiovascular assessment are: Heart rate and rhythm Heart sounds (S1, S2, murmurs) Peripheral pulses Edema (peripheral) Blood pressure

    Time frame: From first dose through Post-Study Visit (up to Day 33)

  6. For Physical examination to evaluate Respiratory

    For Respiratory assessment are: Respiratory rate and effort Chest expansion symmetry Breath sounds (normal, wheeze, crackles) Use of accessory muscles

    Time frame: From first dose through Post-Study Visit (up to Day 33)

  7. For Physical examination to evaluate Gastrointestinal

    For Gastrointestinal assessment are: Abdominal inspection (distension, scars) Palpation (tenderness, masses, organomegaly) Percussion (fluid, liver span) Bowel sounds

    Time frame: From first dose through Post-Study Visit (up to Day 33)

  8. For Physical examination to evaluate Renal

    For Renal assessment are: Flank tenderness (costovertebral angle) Bladder distension Urinary symptoms

    Time frame: From first dose through Post-Study Visit (up to Day 33)

  9. For Physical examination to evaluate Neurological

    For Neurological assessment are: Mental status (orientation, cognition) Cranial nerves (if detailed exam required) Motor function (strength, tone) Sensory function Reflexes Coordination and gait

    Time frame: From first dose through Post-Study Visit (up to Day 33)

  10. For Physical examination to evaluate Musculoskeletal

    For Musculoskeletal assessment are: Joint range of motion Swelling or deformities Muscle strength Tenderness

    Time frame: From first dose through Post-Study Visit (up to Day 33)

  11. For Physical examination to evaluate Skin

    For Skin assessment are: Color (pallor, cyanosis, jaundice) Rashes or lesions Texture and turgor Ulcers or scars

    Time frame: From first dose through Post-Study Visit (up to Day 33)

  12. For Vital signs (body temperature (tympanic)

    For body temperature (tympanic) the measurement of unit is degree Celsius

    Time frame: From first dose through Post-Study Visit (up to Day 33)

  13. For Vital signs (Pulse Rate)

    For Pulse Rate the measurement of unit is - beats/min

    Time frame: From first dose through Post-Study Visit (up to Day 33)

  14. For Vital signs (Systolic/Diastolic blood pressure)

    For Systolic/Diastolic blood pressure the measurement of unit is - mmHg

    Time frame: From first dose through Post-Study Visit (up to Day 33)

  15. For 12-lead ECG (electrocardiogram)

    The investigator evaluates heart rate (rate and regularity), waveform shape, and overall rhythm; QTcF (msec) is used in the screening criteria will be collectively assessed

    Time frame: From first dose through Post-Study Visit (up to Day 33)

  16. For Clinical Laboratory Test which includes Urinalysis

    For Urinalysis - Dipstick + microscopy

    Time frame: From first dose through Post-Study Visit (up to Day 33)

  17. For Clinical Laboratory Test which includes the Coagulation

    For Coagulation - Prothrombin Time (PT) (INR), Activated Partial Thromboplastin Time (aPTT)

    Time frame: From first dose through Post-Study Visit (up to Day 33)

  18. For Clinical Laboratory Test which includes the Blood chemistry

    For Blood chemistry the test performed will be Calcium, phosphate, glucose, urate, cholesterol, total protein, albumin, total bilirubin, Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Gamma-Glutamyl Transferase (γ-GT), Creatine Phosphokinase (CPK), Urea, Lactate Dehydrogenase (LDH), creatinine, Estimated Glomerular Filtration Rate (eGFR) (CKD-EPI), sodium, potassium, chloride, triglyceride, Low-Density Lipoprotein Cholesterol (LDL) \& High-Density Lipoprotein Cholesterol (HDL)

    Time frame: From first dose through Post-Study Visit (up to Day 33)

  19. For Clinical Laboratory Test which includes the Hematology

    For Hematology the test performed will be white blood cells with differential, Red blood cells, hemoglobin, hematocrit \& platelet

    Time frame: From first dose through Post-Study Visit (up to Day 33)

  20. Pharmacokinetic Parameters of SCB0020160 for Cmax

    The results of the outcome are collectively measured

    Time frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort

  21. Pharmacokinetic Parameters of SCB0020160 for Tmax

    The results of the outcome are collectively measured

    Time frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort

  22. Pharmacokinetic Parameters of SCB0020160 for AUClast

    The results of the outcome are collectively measured

    Time frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort

  23. Pharmacokinetic Parameters of SCB0020160 for AUCinf

    The results of the outcome are collectively measured

    Time frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort

  24. Pharmacokinetic Parameters of SCB0020160 for t½

    The results of the outcome are collectively measured

    Time frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort

  25. Pharmacokinetic Parameters of SCB0020160 for CL/F

    The results of the outcome are collectively measured

    Time frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort

  26. Pharmacokinetic Parameters of SCB0020160 for Vz/F

    The results of the outcome are collectively measured

    Time frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort

  27. Pharmacokinetic Parameters of SCB0020160 for MRT

    The results of the outcome are collectively measured

    Time frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort

Secondary outcomes

  1. Comparison of pharmacokinetic parameters for Cmax of SCB0020160 under fasting and fed conditions following a single oral dose.

    The results of the outcome are collectively measured

    Time frame: Up to Day 29.

  2. Comparison of pharmacokinetic parameters for Tmax of SCB0020160 under fasting and fed conditions following a single oral dose.

    The results of the outcome are collectively measured

    Time frame: Up to Day 29.

  3. Comparison of pharmacokinetic parameters for Tlag of SCB0020160 under fasting and fed conditions following a single oral dose.

    The results of the outcome are collectively measured

    Time frame: Up to Day 29.

  4. Comparison of pharmacokinetic parameters for AUClast of SCB0020160 under fasting and fed conditions following a single oral dose.

    The results of the outcome are collectively measured

    Time frame: Up to Day 29.

  5. Comparison of pharmacokinetic parameters for AUCinf of SCB0020160 under fasting and fed conditions following a single oral dose.

    The results of the outcome are collectively measured

    Time frame: Up to Day 29.

  6. Comparison of pharmacokinetic parameters for MRT of SCB0020160 under fasting and fed conditions following a single oral dose.

    The results of the outcome are collectively measured

    Time frame: Up to Day 29.

07

Study locations

1 site
  • CMAX Clinical Research Pty Ltd Ground Floor, 21-24 North Terrace
    Adelaide, South Australia 5000, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jun 2027, 11 months later.

Of 338 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 11 months is above that.

Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2026
First posted
Jul 2, 2026
StartEst.
Jun 29, 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07682337
Lead sponsor
SCBIO Inc.
Responsible party
Sponsor
First posted
Jul 2, 2026
Start date
Jun 29, 2026 (estimated)
Primary completion
Jun 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Jul 2, 2026

Study contacts

Dr. Thomas Polasek
Contact
Thomas.Polasek@cmax.com.au
+61558162715

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion